CLDX vs. MYGN, NTLA, QDEL, NEOG, RIOT, AWH, LNTH, GH, RCKT, and ASTH
Should you be buying Celldex Therapeutics stock or one of its competitors? The main competitors of Celldex Therapeutics include Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), QuidelOrtho (QDEL), Neogen (NEOG), Riot Platforms (RIOT), Aspira Women's Health (AWH), Lantheus (LNTH), Guardant Health (GH), Rocket Pharmaceuticals (RCKT), and Astrana Health (ASTH).
Myriad Genetics (NASDAQ:MYGN) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, community ranking, dividends, media sentiment, valuation and earnings.
99.0% of Myriad Genetics shares are held by institutional investors. 2.0% of Myriad Genetics shares are held by insiders. Comparatively, 3.7% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Myriad Genetics has a net margin of -34.96% compared to Myriad Genetics' net margin of -2,054.46%. Celldex Therapeutics' return on equity of -8.03% beat Myriad Genetics' return on equity.
Celldex Therapeutics received 135 more outperform votes than Myriad Genetics when rated by MarketBeat users. Likewise, 74.84% of users gave Celldex Therapeutics an outperform vote while only 53.46% of users gave Myriad Genetics an outperform vote.
Celldex Therapeutics has lower revenue, but higher earnings than Myriad Genetics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Myriad Genetics had 6 more articles in the media than Celldex Therapeutics. MarketBeat recorded 6 mentions for Myriad Genetics and 0 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.34 beat Myriad Genetics' score of 0.00 indicating that Myriad Genetics is being referred to more favorably in the media.
Myriad Genetics currently has a consensus target price of $23.17, indicating a potential upside of 16.77%. Celldex Therapeutics has a consensus target price of $66.00, indicating a potential upside of 57.11%. Given Myriad Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than Myriad Genetics.
Myriad Genetics has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500.
Summary
Myriad Genetics and Celldex Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Celldex Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Celldex Therapeutics Competitors List
Related Companies and Tools
